Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3113421 | 0.89 | MAPK14 (0.53) | MAPK14 | |
| SCHEMBL1140575 | 0.85 | MAPK14 (0.52) | MAPK14ALDH1A1TSHRMAPK1POLB | |
| SCHEMBL3339157 | 0.85 | MAPK14 (0.52) | MAPK14ALDH1A1TSHRMAPK1POLB | |
| SCHEMBL3113519 | 0.85 | MAPK14 (0.67) | MAPK14 | |
| SCHEMBL3111120 | 0.84 | MAPK14 (0.53) | MAPK14 | |
| SCHEMBL3100474 | 0.84 | MAPK14 (0.45) | MAPK14ALDH1A1TSHRMAPK1POLB | |
| SCHEMBL3100487 | 0.84 | MAPK14 (0.45) | MAPK14ALDH1A1TSHRMAPK1POLB | |
| SCHEMBL3115942 | 0.82 | MAPK14 (0.52) | MAPK14ALDH1A1TSHRMAPK1POLB | |
| SCHEMBL1140231 | 0.79 | MAPK14 (0.80) | MAPK14 | |
| SCHEMBL3341835 | 0.79 | MAPK14 (0.65) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256120-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB | 2010-10-07 | — | — | US | claimed |
| US-20100256120-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB | 2010-10-07 | — | — | US | disclosed |
| US-20100152169-A1 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
| US-7696215-B2 | 4-oxoquinazolin-3-yl benzamide derivatives for the treatment of cytokine diseases | ASTRAZENECA AB (SE) | 2010-04-13 | — | — | US | disclosed |
| US-20090124604-A1 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | disclosed |
| EP-1915350-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| EP-1856062-A1 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE MEDIATED DISEASES | AstraZeneca AB (SE) | 2007-11-21 | — | — | EP | disclosed |
| WO-2007020411-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006090143-A1 | 4-0X0QUINAZ0LIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES | ASTRAZENECA AB (SE) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152169-A1 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES | IL2, IL1A, IL2RA | MAPK14 1418/4885ALDH1A1 358/4885TSHR 1030/4885 |
| US-20090124604-A1 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES | IL2, IL1A, IL1B | MAPK14 1400/4885ALDH1A1 395/4885TSHR 1036/4885 |
| US-20100256120-A1 | AMIDE DERIVATIVES | IL1B, IL1A, IL6 | MAPK14 2363/4885ALDH1A1 161/4885TSHR 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.